News
New service to allow women with cancer in Hong Kong to preserve ovarian tissue
Ovarian tissue freezing is a technique that can offer female cancer patients the chance to preserve their fertility
A new service in Hong Kong will allow female cancer patients to preserve their ovarian tissue as a means to regain their fertility after treatment.
Fertility issues are common in women getting cancer treatment as a result of chemotherapy medicines which can affect patients’ ability to become pregnant.
Often women in need of treatment do not have time to freeze their eggs or embryos, meaning they would not know whether they could have children until after finishing therapy. Ovarian tissue cryopreservation could, in this case, be a promising option.
The procedure, now available at a Hong Kong assisted reproductive technology unit, consists of a small operation to remove some ovarian tissue which is then frozen. The tissue may later be thawed and placed back into the woman’s body once the cancer treatment is finished.
“Before the patients undergo any kind of chemotherapy or treatment that can affect their reproductive ability, we can carry out surgery to extract ovarian tissue for preservation,” Dr Jacqueline Chung Pui-wah, associate professor of Chinese University’s department of obstetrics and gynaecology, told South China Morning Post.
“If in the future, they wish to have children after their recovery, we can carry out another operation to transplant the tissue on the ovary surface so that they can reproduce again.”
Chung’s team had been assessing the feasibility of implementing ovarian tissue cryopreservation in Hong Kong since 2019.
The researchers collected and froze 52 ovarian tissue samples from 12 patients, aged 29 to 41, which were later transplanted into 34 mice.
The findings, published in the Hong Kong Medical Journal in February, showed that most of the tissue remained viable after transplant.
Ovarian tissue cryopreservation has already been offered in countries such as Singapore, Thailand and the US for about 15 years. However, Hong Kong had only provided sperm, egg or embryo cryopreservation in the past.
Success rates are similar to standard fertility treatments such as IVF. Although the treatment remains relatively new, scientists say the results are extremely promising.
While acknowledging the importance of the procedure, Chung warned that the chance of getting pregnant after the ovarian tissue was transplanted back into the patient’s body would depend on many factors, including age, uterus health and embryo quality.
It was also possible that the ovarian tissue extracted before the cancer treatment could contain cancerous cells, she said, adding that pathologists would need to examine the tissue before transplant.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Wellness4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur5 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health







1 Comment